Evidence map›Paper›PMID 29685106›Full record

ArticleBMC pregnancy and childbirth2018

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015.

Suvanna Asavapiriyanont, Wanitchaya Kittikraisak, Piyarat Suntarattiwong, Darunee Ditsungnoen, Surasak Kaoiean, Podjanee Phadungkiatwatana, Nattinee Srisantiroj, Tawee Chotpitayasunondh, Fatimah S Dawood, Kim A Lindblade

Open access · goldAbstract read
In one paragraph

Article in BMC pregnancy and childbirth, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Suvanna AsavapiriyanontRajavithi Hospital, Bangkok, Thailand.
Wanitchaya KittikraisakInfluenza Program, Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand. glr9@cdc.gov.
Piyarat SuntarattiwongQueen Sirikit National Institute of Child Health, Bangkok, Thailand.
Darunee DitsungnoenInfluenza Program, Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Surasak KaoieanRajavithi Hospital, Bangkok, Thailand.
Podjanee PhadungkiatwatanaRajavithi Hospital, Bangkok, Thailand.
Nattinee SrisantirojRajavithi Hospital, Bangkok, Thailand.
Tawee ChotpitayasunondhQueen Sirikit National Institute of Child Health, Bangkok, Thailand.
Fatimah S DawoodInfluenza Division, U.S. Centers for Disease Control and Prevention, Atlanta, USA.
Kim A LindbladeInfluenza Program, Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Rajavithi Hospital · THCenters for Disease Control and Prevention · USMinistry of Public Health · THQueen Sirikit National Institute of Child Health · TH

Funding

CDC HHS 5U01GH000152
6 · The paper itself

Abstract

backgroundThailand recommends influenza vaccination among pregnant women. We conducted a cohort study to determine if the prevalence of adverse events following immunization (AEFIs) with influenza vaccine among Thai pregnant women was similar to that often cited among healthy adults.

methodsWomen who were ≥17 gestational weeks and ≥18 years of age were recruited. Demographic and health history data were collected using structured questionnaires. Women were provided with symptom diary, ruler to measure local reaction(s), and thermometer to measure body temperature. AEFIs were defined as any new symptom/abnormality occurring within four weeks after vaccination. The diaries were abstracted for frequency, duration, and level of discomfort/inconvenience of the AEFIs. Serious adverse events (SAEs) and the likelihood of AEFIs being associated with vaccination were determined using standard definitions.

resultsAmong 305 women enrolled between July-November 2015, median age was 29 years. Of these, 223 (73%) were in their third trimester, 271 (89%) had completed secondary school or higher, and 20 (7%) reported ≥1 pre-existing conditions. AEFIs were reported in 134 women (44%; 95% confidence interval [CI] 38-50%). Soreness at the injection site (74, 24%; CI 19-29%), general weakness (50, 16%; CI 12-21%), muscle ache (49, 16%; CI 12-21%), and headache (45, 15%; CI 1-19%) were most common. Of those with AEFIs, 120 (89%) reported symptom/abnormality occurred on day 0 or day 1 following vaccination. Ten women (7%) reported the AEFIs affected daily activities. The AEFIs generally spontaneously resolved within 24 h of onset. There were two vaccine-unrelated SAEs. Of 294 women with complete follow-up, 279 (95%) had term deliveries, 12 (4%) had preterm deliveries, and 3 (1%) had miscarriage or stillbirth.

conclusionIn our cohort, AEFIs with influenza vaccine occurred with similar frequency to those reported among healthy adults in other studies, and were generally mild and self-limited. No influenza vaccine-associated SAEs were identified.

Indexed as

AdultDrug-Related Side Effects and Adverse ReactionsFemaleHumansInfluenza, HumanInfluenza VaccinesPregnancyPregnancy Complications, InfectiousPrevalenceThailandYoung AdultInfluenza VaccinesInfluenzaPregnant womenThailandTolerabilityVaccination

Identifiers

PMID29685106
PMCPMC5913790
OpenAlexW2800839401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.